0
0

Vital Medication Affordability Act

12/30/2022, 7:04 AM

Congressional Summary of S 2814

Vital Medication Affordability Act

This bill establishes pricing for insulin and injectable epinephrine provided at federally qualified health centers (community-based health providers in underserved areas) that participate in the 340B drug pricing program.

Specifically, such centers must provide insulin and injectable epinephrine at or below the price paid by the center, plus a minimal administration fee, to patients with a household income that is not more than 350% of the federal poverty level and who either

  • have a health insurance plan with a cost-sharing requirement of more than 20% of the total amount charged for such drugs,
  • have a high unmet deductible under a health insurance plan, or
  • do not have a health insurance plan.

Current Status of Bill S 2814

Bill S 2814 is currently in the status of Bill Introduced since September 23, 2021. Bill S 2814 was introduced during Congress 117 and was introduced to the Senate on September 23, 2021.  Bill S 2814's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of September 23, 2021

Bipartisan Support of Bill S 2814

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 2814

Primary Policy Focus

Health

Alternate Title(s) of Bill S 2814

Vital Medication Affordability Act
A bill to provide for affordable access to insulin and epinephrine.
Vital Medication Affordability Act

Comments